Wegovy vs Zepbound: Semaglutide vs Tirzepatide for Weight Loss

Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are both FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. They are currently the two most effective non-surgical weight-loss treatments available. But the data shows they are not equivalent — tirzepatide consistently produces more weight loss across clinical trials. Here is what the evidence says and what it means in practice.

Quick Reference: Wegovy vs Zepbound

• Wegovy (semaglutide 2.4 mg): single GLP-1 agonist. Average weight loss of 14.9% in STEP 1.
• Zepbound (tirzepatide up to 15 mg): dual GIP/GLP-1 agonist. Average weight loss of 22.5% in SURMOUNT-1.
• Both are once-weekly SubQ injections with auto-injector pens.
• GI side effects are the primary tolerability concern with both.
• Wegovy has cardiovascular outcome data (SELECT trial). Zepbound does not yet.
• Weight regain after stopping is documented for both medications.

Comparison Table

Mechanism Differences

Both medications reduce appetite and slow gastric emptying through GLP-1 receptor activation. The difference is that Zepbound adds GIP receptor agonism on top.

Wegovy sustains GLP-1 signaling for a full week. This reduces hunger, increases post-meal satiety, slows the rate at which food leaves your stomach, and modulates reward-related eating behavior through central nervous system pathways. At 2.4 mg — the weight management dose — semaglutide creates substantial and sustained appetite reduction.

Zepbound activates both GIP and GLP-1 receptors. The GIP component appears to improve insulin sensitivity, influence fat cell metabolism, and potentially enhance energy expenditure. Tirzepatide's molecular backbone is actually based on the GIP peptide sequence, modified to also bind GLP-1 receptors. This is not a small detail — it means the drug's primary pharmacological identity leans toward GIP, with GLP-1 activity added on.

The clinical implication of dual agonism is straightforward: more weight loss, more consistently, across a broader patient population. Whether the additional GIP activity also confers metabolic benefits beyond what weight loss alone would explain is an active area of research.

Clinical Trial Results

STEP 1 (Wegovy)

Published in the New England Journal of Medicine in 2021, STEP 1 enrolled 1,961 adults with BMI of 30 or greater (or 27+ with at least one comorbidity) who did not have diabetes.

Key findings at 68 weeks:

• Mean weight loss: -14.9% with semaglutide 2.4 mg vs -2.4% with placebo
• 86% of semaglutide participants lost at least 5% body weight
• 69% lost at least 10%
• 50% lost at least 15%
• 32% lost at least 20% body weight

Participants also received lifestyle counseling. The placebo group's 2.4% weight loss reflects the effect of counseling alone.

SURMOUNT-1 (Zepbound)

Published in the New England Journal of Medicine in 2022, SURMOUNT-1 enrolled 2,539 adults with BMI of 30 or greater (or 27+ with comorbidity), also without diabetes.

Key findings at 72 weeks:

• Mean weight loss at 5 mg: -16.0% (vs -3.1% placebo)
• Mean weight loss at 10 mg: -21.4%
• Mean weight loss at 15 mg: -22.5%
• At 15 mg: 96% lost at least 5%, 85% lost at least 10%, 73% lost at least 15%
• 63% lost at least 20% body weight at 15 mg

Cross-Trial Comparison Caveats

STEP 1 and SURMOUNT-1 were not head-to-head trials. They had different enrollment periods, slightly different patient populations, and different trial durations (68 vs 72 weeks). Cross-trial comparisons are inherently imperfect.

That said, the magnitude of the difference is large enough — and consistent enough across subgroups and secondary endpoints — that most clinicians and researchers accept that tirzepatide produces meaningfully more weight loss than semaglutide at their respective maximum doses. The SURMOUNT-5 trial, which is a direct head-to-head comparison of tirzepatide vs semaglutide for obesity, has been completed and confirms tirzepatide's superiority for weight loss.

Weight Regain After Stopping

STEP 4 studied what happens when semaglutide is discontinued. Participants who switched from semaglutide to placebo regained approximately two-thirds of their lost weight within 48 weeks. Similar weight regain dynamics are expected with tirzepatide — the SURMOUNT-4 study showed comparable regain patterns.

This is not a failure of the medications. It reflects the biology of obesity: the neurohormonal drivers of weight regain persist when the medication is removed. Both drugs work as long as you take them. Plan accordingly.

Dosing Comparison

Wegovy titration schedule:

1. 0.25 mg weekly (weeks 1-4)
2. 0.5 mg weekly (weeks 5-8)
3. 1 mg weekly (weeks 9-12)
4. 1.7 mg weekly (weeks 13-16)
5. 2.4 mg weekly (maintenance)

Time to maintenance dose: 16 weeks. There is only one maintenance dose — 2.4 mg. You either tolerate it or you discuss alternatives with your prescriber.

Zepbound titration schedule:

1. 2.5 mg weekly (weeks 1-4)
2. 5 mg weekly (weeks 5-8) — first potential maintenance dose
3. 7.5 mg weekly (weeks 9-12)
4. 10 mg weekly (weeks 13-16) — second potential maintenance dose
5. 12.5 mg weekly (weeks 17-20)
6. 15 mg weekly (week 21+) — maximum dose

Time to maximum dose: 20 weeks minimum. But here's the practical advantage: Zepbound has three labeled maintenance doses (5, 10, and 15 mg). If you get meaningful weight loss at 10 mg with tolerable side effects, you can stay there. This flexibility is valuable for patients who experience dose-limiting GI symptoms.

Both use auto-injector pens that require no mixing or needle handling. Injection is SubQ into the abdomen, thigh, or upper arm. Rotate sites with each injection.

Side Effects Comparison

GI side effects dominate the adverse event profile for both medications. The pattern is similar: symptoms are worst during titration, improve at stable doses, and are the primary reason patients discontinue treatment.

Nausea: Wegovy's STEP 1 trial reported nausea in 44% of participants (vs 18% placebo). Zepbound's SURMOUNT-1 reported 24-33% depending on dose. The higher rate with Wegovy may partly reflect the faster titration schedule and single maintenance dose — there's less room to find a tolerable middle ground.

Diarrhea: Reported in 30% of Wegovy participants vs 18-25% for Zepbound. The rates are high for both, but most cases are mild to moderate and transient.

Constipation: Roughly equal — 24% for Wegovy, 17-23% for Zepbound. GI motility changes cut both ways.

Vomiting: 24% for Wegovy, 9-13% for Zepbound. This is one of the more notable differences and may contribute to Wegovy's slightly higher discontinuation rate for adverse events.

Injection site reactions: Uncommon with both. When they occur, they're typically mild erythema lasting less than 24 hours.

Gallbladder events: Both medications increase the risk of cholelithiasis (gallstones) due to rapid weight loss. This is a class effect of effective obesity treatments, not unique to GLP-1 medications. Reported rates are low (1-3%) but worth monitoring, especially if you have a history of gallbladder disease.

Pancreatitis: Rare with both medications. Both carry label warnings. The absolute risk increase is small, but report any severe, persistent abdominal pain immediately.

Cardiovascular Considerations

Wegovy has a significant data advantage here. The SELECT trial (2023) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with established cardiovascular disease and overweight/obesity, regardless of diabetes status. This led to an expanded FDA indication for cardiovascular risk reduction.

Zepbound does not yet have cardiovascular outcomes data. Eli Lilly's SURPASS-CVOT for tirzepatide in diabetes is ongoing, and a dedicated obesity cardiovascular outcomes trial (SURMOUNT-MMO) has been initiated. Until these report, Wegovy is the only weight management medication with proven cardiovascular benefit.

Practical Tracking Considerations

Weekly injections sound simple, but the real-world challenges of weight management treatment go well beyond remembering shot day.

Track these weekly:

• Injection date, time, dose, and site
• Body weight (same time, same conditions, same scale)
• GI symptoms and severity (use a simple 0-3 scale)
• Appetite and satiety changes (subjective but valuable over time)
• Physical activity (type and duration)

Track these monthly or at each visit:

• Waist circumference
• Blood pressure
• Fasting glucose (or CGM summary if available)
• Any new or worsening symptoms

Track during dose changes:

• Date of each dose increase
• Symptom timeline relative to the increase
• Whether you needed to hold at a dose longer than the minimum titration period

The reason tracking matters more here than with many medications: weight management treatment is iterative. Your prescriber is making decisions about dose escalation, maintenance dose selection, and whether to continue, switch, or add therapies based on how you're responding. The more data you bring, the better those decisions will be.

Which Is Right for You

Zepbound may be preferred when:

• Maximum weight loss is the primary goal
• You want more flexibility in maintenance dosing
• You've tried Wegovy without adequate response
• You tolerate GI side effects well enough to titrate fully

Wegovy may be preferred when:

• You have established cardiovascular disease and want proven CV risk reduction
• Your insurance covers Wegovy but not Zepbound
• You prefer a simpler dosing scheme (one maintenance dose)
• You're already responding well to semaglutide

For both medications:

• You need a BMI of 30+ or BMI 27+ with at least one weight-related comorbidity
• You should be receiving concurrent lifestyle intervention (diet, exercise, behavioral counseling)
• Plan for long-term use — discontinuation leads to weight regain
• Regular follow-up with your prescriber is essential

Neither medication is a standalone solution. Both work best as part of a structured treatment plan that includes dietary changes, physical activity, and ongoing clinical monitoring.

Frequently Asked Questions

How much weight can you lose on Zepbound vs Wegovy?

In their respective pivotal trials, Zepbound (tirzepatide 15 mg) produced average weight loss of 22.5% of body weight over 72 weeks (SURMOUNT-1), while Wegovy (semaglutide 2.4 mg) produced 14.9% over 68 weeks (STEP 1). These are cross-trial comparisons and should be interpreted with caution, but the difference is consistent across multiple data points.

Can you switch from Wegovy to Zepbound?

Yes. Your prescriber will typically start Zepbound at the lowest dose (2.5 mg) and titrate up, regardless of your Wegovy dose. There's no required washout period. Expect some GI adjustment during the transition as your body adapts to dual-receptor activation.

Are Wegovy and Zepbound covered by insurance?

Coverage varies widely by plan. Many commercial insurance plans cover one or both, but Medicare Part D does not cover weight-loss medications as of early 2026. Both manufacturers offer savings programs that can significantly reduce out-of-pocket cost for commercially insured patients.

Do you regain weight after stopping Wegovy or Zepbound?

Yes, weight regain after discontinuation is well-documented for both medications. The STEP 4 trial showed that participants who stopped semaglutide regained approximately two-thirds of their lost weight within a year. Similar patterns are expected with tirzepatide. These medications work while you take them — they are not cures for obesity.

Sources

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
3. Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224
4. Garvey WT, et al. Tirzepatide for the Treatment of Obesity — SURMOUNT-2. Lancet. 2023. doi:10.1016/S0140-6736(23)01200-X
5. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023. doi:10.1056/NEJMoa2307563

Whether you're on Wegovy, Zepbound, or transitioning between them, consistent tracking is what separates patients who optimize their results from those who guess. DoneDose logs your injections, tracks side effects and weight trends, and keeps your treatment data organized — ready for every prescriber visit.